Antibody shot tested in vulnerable kids to block COVID-19
NCT ID NCT04992273
Summary
This study tested a single shot of lab-made antibodies (casirivimab and imdevimab) to see if it could help prevent severe COVID-19 in high-risk children under 12. Researchers gave the shot to a small group of kids and tracked how long the drug stayed in their bodies and checked for any side effects. The study was terminated early and did not test if the shot actually prevented COVID-19 infection.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Research Center, Inc
Anaheim, California, 92805, United States
-
Batchelor's Children's Research Institute
Miami, Florida, 33136, United States
-
Coastal Pediatric Research
Charleston, South Carolina, 29414, United States
-
Jacobi Medical Center
The Bronx, New York, 10461, United States
-
Regeneron Research Site
Richmond, Virginia, 23226, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
Stony Brook University Hospital
Stony Brook, New York, 11794, United States
Conditions
Explore the condition pages connected to this study.